deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02910102

Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia

Sponsor: Axovant Sciences Ltd.

Conditions Alzheimer's Disease Dementia With Lewy Bodies Parkinson's Disease Dementia
Interventions Placebo RVT-101 35 mg
Updated 17 times since 2017 Last updated: Apr 17, 2020 Started: Oct 31, 2016 Primary completion: Nov 30, 2017 Completion: Nov 30, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Alzheimer's Disease and Dementia With Lewy Bodies and is currently completed. Axovant Sciences Ltd. leads this study, which shows 17 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Jan 2018 · 3 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~May 2020 · 23 months · monthly snapshot~May 2020 – ~Dec 2020 · 7 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

▶ Show 12 earlier versions

  1. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE2

  2. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE2

  3. May 2020 — Dec 2020 [monthly]

    Completed PHASE2

  4. Jun 2018 — May 2020 [monthly]

    Completed PHASE2

  5. Jan 2018 — Jun 2018 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  6. Oct 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE2

  7. Sep 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  9. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

  10. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

  11. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Axovant Sciences Ltd.
Data source: Sio Gene Therapies

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations